Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Vaccines (Basel) ; 11(12)2023 Dec 01.
Article in English | MEDLINE | ID: mdl-38140205

ABSTRACT

BACKGROUND: The WHO recommended the use of the RTS,S/AS01 malaria vaccine (RTS,S) based on a pilot evaluation in routine use in Ghana, Kenya, and Malawi. A longitudinal qualitative study was conducted to examine facilitators and barriers to uptake of a 4-dose RTS,S schedule. METHODS: A cohort of 198 caregivers of RTS,S-eligible children from communities where RTS,S was provided through the pilot were interviewed three times over a ≈22-month, 4-dose schedule. The interviews examined caregiver perceptions and behaviors. Children's vaccination history was obtained to determine dose uptake. RESULTS: 162 caregivers remained at round 3 (R3); vaccination history was available for 152/162 children. Despite early rumors/fears, the uptake of initial doses was high, driven by vaccine trust. Fears dissipated by R2, replaced with an enthusiasm for RTS,S as caregivers perceived its safety and less frequent and severe malaria. By R3, 98/152 children had received four doses; 34 three doses; 9 one or two doses; and 11 zero doses. The health system and information barriers were important across all under-dose cases. Fears about AEFIs/safety were important in zero-, one-, and two-dose cases. Competing life/livelihood demands and complacency were found in three-dose cases. Regardless of the doses received, caregivers had positive attitudes towards RTS,S by R3. CONCLUSIONS: Findings from our study will help countries newly introducing the vaccine to anticipate and preempt reasons for delayed acceptance and missed RTS,S doses.

2.
Vaccine ; 31 Suppl 2: B122-8, 2013 Apr 18.
Article in English | MEDLINE | ID: mdl-23598473

ABSTRACT

In 2010, global immunization partners posed the question, "Do new vaccine introductions (NVIs) have positive or negative impacts on immunization and health systems of countries?" An Ad-hoc Working Group was formed for WHO's Strategic Advisory Group of Experts on immunization (SAGE) to examine this question through five approaches: a published literature review, a grey literature review, in-depth interviews with regional and country immunization staff, in-depth studies of recent NVIs in 3 countries, and a statistical analysis of the impact of NVI on DTP3 coverage in 176 countries. The WHO Health System Framework of building blocks was used to organize the analysis of these data to assess potential areas of impact of NVI on health systems. In April 2012, the Ad-hoc Working Group presented its findings to SAGE. While reductions in disease burden and improvements in disease and adverse events surveillance, training, cold chain and logistics capacity and injection safety were commonly documented as beneficial impacts, opportunities for strengthening the broader health system were consistently missed during NVI. Weaknesses in planning for human and financial resource needs were highlighted as a concern. Where positive impacts on health systems following NVI occurred, these were often in areas where detailed technical guidance or tools and adequate financing were available. SAGE supported the Ad-hoc Working Group's conclusion that future NVI should explicitly plan to optimize and document the impact of NVI on broader health systems. Furthermore, opportunities for improving integration of delivery of immunization services, commodities, and messages with other parts of the health system should be actively sought with the recognition that integration is a bidirectional process. To avoid the gaps in planning for NVI that can compromise existing immunization and health systems, donors and partners should provide sufficient and timely support to facilitate country planning. Areas for future research were also identified. Finally, to support countries in using NVI as an opportunity to strengthen immunization and health systems, the WHO guidance for countries on new vaccine introduction is being updated to reflect ways this might be accomplished.


Subject(s)
Health Planning/organization & administration , Immunization Programs/organization & administration , Vaccination/economics , Vaccines , Government Programs , Guatemala , Humans , Immunization Programs/economics , Kenya , Mali , Models, Statistical , Systems Integration
3.
Health Policy Plan ; 27 Suppl 2: ii17-26, 2012 May.
Article in English | MEDLINE | ID: mdl-22513729

ABSTRACT

Low- and lower-middle-income countries are faced with a large and increasingly complicated portfolio of vaccines to introduce into their national immunization programmes. Countries must also incorporate their vaccine introduction plans into donor-required assessments and multi-year plans. An international workshop and series of key informant interviews were conducted to explore the interest, opportunities and challenges for the proactive planning of multiple vaccine introduction within a single planning cycle and the underlying processes for planning the introduction of new vaccines. The study found limited experience with this proactive planning process in low-income countries and used the experience of two lower-middle-income countries in simultaneously introducing rotavirus and pneumococcal vaccines to highlight the importance of integrating the planning processes for new vaccine introduction into broader immunization systems planning and financing. The study's findings suggest that this strategy for vaccine introduction may have promise for accelerating the pace of new vaccine introduction. However, we also show that realizing these benefits will require improved logistic and financial planning activities and continued actions to resolve uncertainties in the relationships between donors, technical agencies, and the national immunization programmes.


Subject(s)
Developing Countries , Immunization Programs/organization & administration , Vaccines/therapeutic use , Decision Making, Organizational , Education , Humans , Immunization Programs/economics , Policy Making , Vaccines/economics
SELECTION OF CITATIONS
SEARCH DETAIL